nodes	percent_of_prediction	percent_of_DWPC	metapath
Atazanavir—ABCC1—Dactinomycin—testicular cancer	0.135	0.17	CbGbCtD
Atazanavir—ABCC1—Epirubicin—testicular cancer	0.098	0.123	CbGbCtD
Atazanavir—ABCC1—Vinblastine—testicular cancer	0.0848	0.106	CbGbCtD
Atazanavir—ABCC1—Etoposide—testicular cancer	0.0764	0.0957	CbGbCtD
Atazanavir—SLCO1B3—Methotrexate—testicular cancer	0.073	0.0914	CbGbCtD
Atazanavir—ABCC1—Doxorubicin—testicular cancer	0.0521	0.0652	CbGbCtD
Atazanavir—ABCC1—Methotrexate—testicular cancer	0.0505	0.0632	CbGbCtD
Atazanavir—CYP2C9—Ifosfamide—testicular cancer	0.0397	0.0498	CbGbCtD
Atazanavir—ABCB1—Dactinomycin—testicular cancer	0.0327	0.0409	CbGbCtD
Atazanavir—CYP3A4—Ifosfamide—testicular cancer	0.0231	0.0289	CbGbCtD
Atazanavir—ABCB1—Vinblastine—testicular cancer	0.0205	0.0256	CbGbCtD
Atazanavir—CYP2C9—Cisplatin—testicular cancer	0.0193	0.0242	CbGbCtD
Atazanavir—ABCB1—Cisplatin—testicular cancer	0.0188	0.0235	CbGbCtD
Atazanavir—ABCB1—Etoposide—testicular cancer	0.0184	0.0231	CbGbCtD
Atazanavir—ABCB1—Doxorubicin—testicular cancer	0.0126	0.0157	CbGbCtD
Atazanavir—CYP3A4—Vinblastine—testicular cancer	0.0123	0.0154	CbGbCtD
Atazanavir—ABCB1—Methotrexate—testicular cancer	0.0122	0.0153	CbGbCtD
Atazanavir—CYP3A4—Etoposide—testicular cancer	0.011	0.0138	CbGbCtD
Atazanavir—CYP3A4—Doxorubicin—testicular cancer	0.00753	0.00943	CbGbCtD
Atazanavir—Renal failure—Epirubicin—testicular cancer	0.000156	0.000775	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Etoposide—testicular cancer	0.000156	0.000774	CcSEcCtD
Atazanavir—Body temperature increased—Cisplatin—testicular cancer	0.000156	0.000774	CcSEcCtD
Atazanavir—Fatigue—Etoposide—testicular cancer	0.000156	0.000773	CcSEcCtD
Atazanavir—Neuropathy peripheral—Epirubicin—testicular cancer	0.000156	0.000773	CcSEcCtD
Atazanavir—Jaundice—Epirubicin—testicular cancer	0.000155	0.000768	CcSEcCtD
Atazanavir—Stomatitis—Epirubicin—testicular cancer	0.000155	0.000768	CcSEcCtD
Atazanavir—Pain—Etoposide—testicular cancer	0.000155	0.000767	CcSEcCtD
Atazanavir—Constipation—Etoposide—testicular cancer	0.000155	0.000767	CcSEcCtD
Atazanavir—Urinary tract infection—Epirubicin—testicular cancer	0.000154	0.000766	CcSEcCtD
Atazanavir—Neutropenia—Doxorubicin—testicular cancer	0.000154	0.000765	CcSEcCtD
Atazanavir—Hepatitis—Methotrexate—testicular cancer	0.000152	0.000756	CcSEcCtD
Atazanavir—Sweating—Epirubicin—testicular cancer	0.000152	0.000756	CcSEcCtD
Atazanavir—Pollakiuria—Doxorubicin—testicular cancer	0.000152	0.000756	CcSEcCtD
Atazanavir—Haematuria—Epirubicin—testicular cancer	0.000151	0.000752	CcSEcCtD
Atazanavir—Dizziness—Ifosfamide—testicular cancer	0.000151	0.000751	CcSEcCtD
Atazanavir—Urinary tract disorder—Methotrexate—testicular cancer	0.000151	0.000747	CcSEcCtD
Atazanavir—Photosensitivity reaction—Doxorubicin—testicular cancer	0.00015	0.000747	CcSEcCtD
Atazanavir—Hepatobiliary disease—Epirubicin—testicular cancer	0.00015	0.000746	CcSEcCtD
Atazanavir—Weight increased—Doxorubicin—testicular cancer	0.00015	0.000744	CcSEcCtD
Atazanavir—Urethral disorder—Methotrexate—testicular cancer	0.000149	0.000741	CcSEcCtD
Atazanavir—Weight decreased—Doxorubicin—testicular cancer	0.000149	0.00074	CcSEcCtD
Atazanavir—Feeling abnormal—Etoposide—testicular cancer	0.000149	0.000739	CcSEcCtD
Atazanavir—Hyperglycaemia—Doxorubicin—testicular cancer	0.000149	0.000738	CcSEcCtD
Atazanavir—Nausea—Dactinomycin—testicular cancer	0.000148	0.000736	CcSEcCtD
Atazanavir—Gastrointestinal pain—Etoposide—testicular cancer	0.000148	0.000733	CcSEcCtD
Atazanavir—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000146	0.000723	CcSEcCtD
Atazanavir—Vomiting—Ifosfamide—testicular cancer	0.000146	0.000722	CcSEcCtD
Atazanavir—Hypersensitivity—Cisplatin—testicular cancer	0.000145	0.000721	CcSEcCtD
Atazanavir—Renal failure—Doxorubicin—testicular cancer	0.000145	0.000717	CcSEcCtD
Atazanavir—Rash—Ifosfamide—testicular cancer	0.000144	0.000716	CcSEcCtD
Atazanavir—Dermatitis—Ifosfamide—testicular cancer	0.000144	0.000715	CcSEcCtD
Atazanavir—Erythema multiforme—Methotrexate—testicular cancer	0.000144	0.000715	CcSEcCtD
Atazanavir—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000144	0.000715	CcSEcCtD
Atazanavir—Urticaria—Etoposide—testicular cancer	0.000144	0.000713	CcSEcCtD
Atazanavir—Stomatitis—Doxorubicin—testicular cancer	0.000143	0.000711	CcSEcCtD
Atazanavir—Jaundice—Doxorubicin—testicular cancer	0.000143	0.000711	CcSEcCtD
Atazanavir—Abdominal pain—Etoposide—testicular cancer	0.000143	0.000709	CcSEcCtD
Atazanavir—Body temperature increased—Etoposide—testicular cancer	0.000143	0.000709	CcSEcCtD
Atazanavir—Urinary tract infection—Doxorubicin—testicular cancer	0.000143	0.000709	CcSEcCtD
Atazanavir—Hepatitis—Epirubicin—testicular cancer	0.000143	0.000708	CcSEcCtD
Atazanavir—Eye disorder—Methotrexate—testicular cancer	0.000142	0.000707	CcSEcCtD
Atazanavir—Tinnitus—Methotrexate—testicular cancer	0.000142	0.000705	CcSEcCtD
Atazanavir—Hypoaesthesia—Epirubicin—testicular cancer	0.000142	0.000704	CcSEcCtD
Atazanavir—Asthenia—Cisplatin—testicular cancer	0.000142	0.000702	CcSEcCtD
Atazanavir—Cardiac disorder—Methotrexate—testicular cancer	0.000141	0.000702	CcSEcCtD
Atazanavir—Sweating—Doxorubicin—testicular cancer	0.000141	0.000699	CcSEcCtD
Atazanavir—Urinary tract disorder—Epirubicin—testicular cancer	0.000141	0.000699	CcSEcCtD
Atazanavir—Oedema peripheral—Epirubicin—testicular cancer	0.000141	0.000697	CcSEcCtD
Atazanavir—Haematuria—Doxorubicin—testicular cancer	0.00014	0.000695	CcSEcCtD
Atazanavir—Connective tissue disorder—Epirubicin—testicular cancer	0.00014	0.000695	CcSEcCtD
Atazanavir—Urethral disorder—Epirubicin—testicular cancer	0.00014	0.000694	CcSEcCtD
Atazanavir—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000139	0.00069	CcSEcCtD
Atazanavir—Angiopathy—Methotrexate—testicular cancer	0.000138	0.000686	CcSEcCtD
Atazanavir—Immune system disorder—Methotrexate—testicular cancer	0.000138	0.000683	CcSEcCtD
Atazanavir—Mediastinal disorder—Methotrexate—testicular cancer	0.000137	0.000682	CcSEcCtD
Atazanavir—Nausea—Ifosfamide—testicular cancer	0.000136	0.000675	CcSEcCtD
Atazanavir—Diarrhoea—Cisplatin—testicular cancer	0.000135	0.00067	CcSEcCtD
Atazanavir—Erythema multiforme—Epirubicin—testicular cancer	0.000135	0.000669	CcSEcCtD
Atazanavir—Alopecia—Methotrexate—testicular cancer	0.000135	0.000668	CcSEcCtD
Atazanavir—Mental disorder—Methotrexate—testicular cancer	0.000134	0.000662	CcSEcCtD
Atazanavir—Eye disorder—Epirubicin—testicular cancer	0.000133	0.000661	CcSEcCtD
Atazanavir—Hypersensitivity—Etoposide—testicular cancer	0.000133	0.000661	CcSEcCtD
Atazanavir—Tinnitus—Epirubicin—testicular cancer	0.000133	0.00066	CcSEcCtD
Atazanavir—Malnutrition—Methotrexate—testicular cancer	0.000133	0.000658	CcSEcCtD
Atazanavir—Cardiac disorder—Epirubicin—testicular cancer	0.000132	0.000657	CcSEcCtD
Atazanavir—Hepatitis—Doxorubicin—testicular cancer	0.000132	0.000655	CcSEcCtD
Atazanavir—Hypoaesthesia—Doxorubicin—testicular cancer	0.000131	0.000652	CcSEcCtD
Atazanavir—Urinary tract disorder—Doxorubicin—testicular cancer	0.00013	0.000647	CcSEcCtD
Atazanavir—Oedema peripheral—Doxorubicin—testicular cancer	0.00013	0.000645	CcSEcCtD
Atazanavir—Dysgeusia—Methotrexate—testicular cancer	0.00013	0.000645	CcSEcCtD
Atazanavir—Asthenia—Etoposide—testicular cancer	0.00013	0.000644	CcSEcCtD
Atazanavir—Connective tissue disorder—Doxorubicin—testicular cancer	0.00013	0.000643	CcSEcCtD
Atazanavir—Angiopathy—Epirubicin—testicular cancer	0.000129	0.000642	CcSEcCtD
Atazanavir—Urethral disorder—Doxorubicin—testicular cancer	0.000129	0.000642	CcSEcCtD
Atazanavir—Immune system disorder—Epirubicin—testicular cancer	0.000129	0.000639	CcSEcCtD
Atazanavir—Mediastinal disorder—Epirubicin—testicular cancer	0.000129	0.000638	CcSEcCtD
Atazanavir—Back pain—Methotrexate—testicular cancer	0.000128	0.000637	CcSEcCtD
Atazanavir—Pruritus—Etoposide—testicular cancer	0.000128	0.000635	CcSEcCtD
Atazanavir—Alopecia—Epirubicin—testicular cancer	0.000126	0.000625	CcSEcCtD
Atazanavir—Vomiting—Cisplatin—testicular cancer	0.000125	0.000622	CcSEcCtD
Atazanavir—Mental disorder—Epirubicin—testicular cancer	0.000125	0.00062	CcSEcCtD
Atazanavir—Erythema multiforme—Doxorubicin—testicular cancer	0.000125	0.000619	CcSEcCtD
Atazanavir—Rash—Cisplatin—testicular cancer	0.000124	0.000617	CcSEcCtD
Atazanavir—Dermatitis—Cisplatin—testicular cancer	0.000124	0.000617	CcSEcCtD
Atazanavir—Malnutrition—Epirubicin—testicular cancer	0.000124	0.000616	CcSEcCtD
Atazanavir—Diarrhoea—Etoposide—testicular cancer	0.000124	0.000614	CcSEcCtD
Atazanavir—Eye disorder—Doxorubicin—testicular cancer	0.000123	0.000612	CcSEcCtD
Atazanavir—Ill-defined disorder—Methotrexate—testicular cancer	0.000123	0.000611	CcSEcCtD
Atazanavir—Tinnitus—Doxorubicin—testicular cancer	0.000123	0.000611	CcSEcCtD
Atazanavir—Cardiac disorder—Doxorubicin—testicular cancer	0.000122	0.000608	CcSEcCtD
Atazanavir—Flatulence—Epirubicin—testicular cancer	0.000122	0.000607	CcSEcCtD
Atazanavir—Tension—Epirubicin—testicular cancer	0.000122	0.000605	CcSEcCtD
Atazanavir—Dysgeusia—Epirubicin—testicular cancer	0.000122	0.000603	CcSEcCtD
Atazanavir—Nervousness—Epirubicin—testicular cancer	0.000121	0.000598	CcSEcCtD
Atazanavir—Back pain—Epirubicin—testicular cancer	0.00012	0.000596	CcSEcCtD
Atazanavir—Angiopathy—Doxorubicin—testicular cancer	0.00012	0.000594	CcSEcCtD
Atazanavir—Malaise—Methotrexate—testicular cancer	0.00012	0.000594	CcSEcCtD
Atazanavir—Dizziness—Etoposide—testicular cancer	0.00012	0.000593	CcSEcCtD
Atazanavir—Immune system disorder—Doxorubicin—testicular cancer	0.000119	0.000591	CcSEcCtD
Atazanavir—Mediastinal disorder—Doxorubicin—testicular cancer	0.000119	0.00059	CcSEcCtD
Atazanavir—Nausea—Cisplatin—testicular cancer	0.000117	0.000582	CcSEcCtD
Atazanavir—Alopecia—Doxorubicin—testicular cancer	0.000117	0.000579	CcSEcCtD
Atazanavir—Cough—Methotrexate—testicular cancer	0.000116	0.000574	CcSEcCtD
Atazanavir—Mental disorder—Doxorubicin—testicular cancer	0.000116	0.000574	CcSEcCtD
Atazanavir—Ill-defined disorder—Epirubicin—testicular cancer	0.000115	0.000572	CcSEcCtD
Atazanavir—Convulsion—Methotrexate—testicular cancer	0.000115	0.00057	CcSEcCtD
Atazanavir—Vomiting—Etoposide—testicular cancer	0.000115	0.00057	CcSEcCtD
Atazanavir—Malnutrition—Doxorubicin—testicular cancer	0.000115	0.00057	CcSEcCtD
Atazanavir—Agitation—Epirubicin—testicular cancer	0.000114	0.000566	CcSEcCtD
Atazanavir—Rash—Etoposide—testicular cancer	0.000114	0.000566	CcSEcCtD
Atazanavir—Dermatitis—Etoposide—testicular cancer	0.000114	0.000565	CcSEcCtD
Atazanavir—Headache—Etoposide—testicular cancer	0.000113	0.000562	CcSEcCtD
Atazanavir—Flatulence—Doxorubicin—testicular cancer	0.000113	0.000562	CcSEcCtD
Atazanavir—Arthralgia—Methotrexate—testicular cancer	0.000113	0.00056	CcSEcCtD
Atazanavir—Myalgia—Methotrexate—testicular cancer	0.000113	0.00056	CcSEcCtD
Atazanavir—Chest pain—Methotrexate—testicular cancer	0.000113	0.00056	CcSEcCtD
Atazanavir—Tension—Doxorubicin—testicular cancer	0.000113	0.000559	CcSEcCtD
Atazanavir—Dysgeusia—Doxorubicin—testicular cancer	0.000112	0.000558	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000112	0.000557	CcSEcCtD
Atazanavir—Malaise—Epirubicin—testicular cancer	0.000112	0.000556	CcSEcCtD
Atazanavir—Discomfort—Methotrexate—testicular cancer	0.000112	0.000554	CcSEcCtD
Atazanavir—Nervousness—Doxorubicin—testicular cancer	0.000112	0.000554	CcSEcCtD
Atazanavir—Syncope—Epirubicin—testicular cancer	0.000111	0.000552	CcSEcCtD
Atazanavir—Back pain—Doxorubicin—testicular cancer	0.000111	0.000551	CcSEcCtD
Atazanavir—Palpitations—Epirubicin—testicular cancer	0.00011	0.000544	CcSEcCtD
Atazanavir—Confusional state—Methotrexate—testicular cancer	0.000109	0.000542	CcSEcCtD
Atazanavir—Loss of consciousness—Epirubicin—testicular cancer	0.000109	0.000541	CcSEcCtD
Atazanavir—Cough—Epirubicin—testicular cancer	0.000108	0.000538	CcSEcCtD
Atazanavir—Convulsion—Epirubicin—testicular cancer	0.000108	0.000534	CcSEcCtD
Atazanavir—Infection—Methotrexate—testicular cancer	0.000108	0.000534	CcSEcCtD
Atazanavir—Nausea—Etoposide—testicular cancer	0.000107	0.000533	CcSEcCtD
Atazanavir—Hypertension—Epirubicin—testicular cancer	0.000107	0.000532	CcSEcCtD
Atazanavir—Ill-defined disorder—Doxorubicin—testicular cancer	0.000107	0.000529	CcSEcCtD
Atazanavir—Nervous system disorder—Methotrexate—testicular cancer	0.000106	0.000527	CcSEcCtD
Atazanavir—Myalgia—Epirubicin—testicular cancer	0.000106	0.000524	CcSEcCtD
Atazanavir—Chest pain—Epirubicin—testicular cancer	0.000106	0.000524	CcSEcCtD
Atazanavir—Arthralgia—Epirubicin—testicular cancer	0.000106	0.000524	CcSEcCtD
Atazanavir—Agitation—Doxorubicin—testicular cancer	0.000106	0.000524	CcSEcCtD
Atazanavir—Anxiety—Epirubicin—testicular cancer	0.000105	0.000523	CcSEcCtD
Atazanavir—Skin disorder—Methotrexate—testicular cancer	0.000105	0.000522	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000105	0.000521	CcSEcCtD
Atazanavir—Hyperhidrosis—Methotrexate—testicular cancer	0.000105	0.000519	CcSEcCtD
Atazanavir—Discomfort—Epirubicin—testicular cancer	0.000104	0.000518	CcSEcCtD
Atazanavir—Malaise—Doxorubicin—testicular cancer	0.000104	0.000514	CcSEcCtD
Atazanavir—Dry mouth—Epirubicin—testicular cancer	0.000103	0.000513	CcSEcCtD
Atazanavir—Anorexia—Methotrexate—testicular cancer	0.000103	0.000512	CcSEcCtD
Atazanavir—Syncope—Doxorubicin—testicular cancer	0.000103	0.000511	CcSEcCtD
Atazanavir—Confusional state—Epirubicin—testicular cancer	0.000102	0.000507	CcSEcCtD
Atazanavir—Palpitations—Doxorubicin—testicular cancer	0.000102	0.000504	CcSEcCtD
Atazanavir—Oedema—Epirubicin—testicular cancer	0.000101	0.000503	CcSEcCtD
Atazanavir—Loss of consciousness—Doxorubicin—testicular cancer	0.000101	0.000501	CcSEcCtD
Atazanavir—Infection—Epirubicin—testicular cancer	0.000101	0.000499	CcSEcCtD
Atazanavir—Cough—Doxorubicin—testicular cancer	0.0001	0.000497	CcSEcCtD
Atazanavir—Shock—Epirubicin—testicular cancer	9.97e-05	0.000495	CcSEcCtD
Atazanavir—Convulsion—Doxorubicin—testicular cancer	9.95e-05	0.000494	CcSEcCtD
Atazanavir—Nervous system disorder—Epirubicin—testicular cancer	9.94e-05	0.000493	CcSEcCtD
Atazanavir—Hypertension—Doxorubicin—testicular cancer	9.92e-05	0.000492	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Methotrexate—testicular cancer	9.86e-05	0.000489	CcSEcCtD
Atazanavir—Skin disorder—Epirubicin—testicular cancer	9.84e-05	0.000488	CcSEcCtD
Atazanavir—Hyperhidrosis—Epirubicin—testicular cancer	9.8e-05	0.000486	CcSEcCtD
Atazanavir—Insomnia—Methotrexate—testicular cancer	9.79e-05	0.000486	CcSEcCtD
Atazanavir—Chest pain—Doxorubicin—testicular cancer	9.78e-05	0.000485	CcSEcCtD
Atazanavir—Arthralgia—Doxorubicin—testicular cancer	9.78e-05	0.000485	CcSEcCtD
Atazanavir—Myalgia—Doxorubicin—testicular cancer	9.78e-05	0.000485	CcSEcCtD
Atazanavir—Anxiety—Doxorubicin—testicular cancer	9.75e-05	0.000484	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	9.71e-05	0.000482	CcSEcCtD
Atazanavir—Discomfort—Doxorubicin—testicular cancer	9.66e-05	0.000479	CcSEcCtD
Atazanavir—Anorexia—Epirubicin—testicular cancer	9.66e-05	0.000479	CcSEcCtD
Atazanavir—Dyspnoea—Methotrexate—testicular cancer	9.65e-05	0.000479	CcSEcCtD
Atazanavir—Somnolence—Methotrexate—testicular cancer	9.63e-05	0.000478	CcSEcCtD
Atazanavir—Dry mouth—Doxorubicin—testicular cancer	9.57e-05	0.000475	CcSEcCtD
Atazanavir—Dyspepsia—Methotrexate—testicular cancer	9.53e-05	0.000473	CcSEcCtD
Atazanavir—Confusional state—Doxorubicin—testicular cancer	9.45e-05	0.000469	CcSEcCtD
Atazanavir—Decreased appetite—Methotrexate—testicular cancer	9.41e-05	0.000467	CcSEcCtD
Atazanavir—Oedema—Doxorubicin—testicular cancer	9.38e-05	0.000465	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Methotrexate—testicular cancer	9.35e-05	0.000464	CcSEcCtD
Atazanavir—Fatigue—Methotrexate—testicular cancer	9.34e-05	0.000463	CcSEcCtD
Atazanavir—Infection—Doxorubicin—testicular cancer	9.31e-05	0.000462	CcSEcCtD
Atazanavir—Pain—Methotrexate—testicular cancer	9.26e-05	0.000459	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Epirubicin—testicular cancer	9.23e-05	0.000458	CcSEcCtD
Atazanavir—Shock—Doxorubicin—testicular cancer	9.22e-05	0.000458	CcSEcCtD
Atazanavir—Nervous system disorder—Doxorubicin—testicular cancer	9.19e-05	0.000456	CcSEcCtD
Atazanavir—Insomnia—Epirubicin—testicular cancer	9.16e-05	0.000455	CcSEcCtD
Atazanavir—Skin disorder—Doxorubicin—testicular cancer	9.11e-05	0.000452	CcSEcCtD
Atazanavir—Hyperhidrosis—Doxorubicin—testicular cancer	9.06e-05	0.00045	CcSEcCtD
Atazanavir—Dyspnoea—Epirubicin—testicular cancer	9.03e-05	0.000448	CcSEcCtD
Atazanavir—Somnolence—Epirubicin—testicular cancer	9.01e-05	0.000447	CcSEcCtD
Atazanavir—Anorexia—Doxorubicin—testicular cancer	8.94e-05	0.000443	CcSEcCtD
Atazanavir—Feeling abnormal—Methotrexate—testicular cancer	8.92e-05	0.000443	CcSEcCtD
Atazanavir—Dyspepsia—Epirubicin—testicular cancer	8.92e-05	0.000443	CcSEcCtD
Atazanavir—Gastrointestinal pain—Methotrexate—testicular cancer	8.85e-05	0.000439	CcSEcCtD
Atazanavir—Decreased appetite—Epirubicin—testicular cancer	8.81e-05	0.000437	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Epirubicin—testicular cancer	8.75e-05	0.000434	CcSEcCtD
Atazanavir—Fatigue—Epirubicin—testicular cancer	8.74e-05	0.000433	CcSEcCtD
Atazanavir—Constipation—Epirubicin—testicular cancer	8.67e-05	0.00043	CcSEcCtD
Atazanavir—Pain—Epirubicin—testicular cancer	8.67e-05	0.00043	CcSEcCtD
Atazanavir—Urticaria—Methotrexate—testicular cancer	8.6e-05	0.000427	CcSEcCtD
Atazanavir—Abdominal pain—Methotrexate—testicular cancer	8.56e-05	0.000425	CcSEcCtD
Atazanavir—Body temperature increased—Methotrexate—testicular cancer	8.56e-05	0.000425	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Doxorubicin—testicular cancer	8.54e-05	0.000424	CcSEcCtD
Atazanavir—Insomnia—Doxorubicin—testicular cancer	8.48e-05	0.000421	CcSEcCtD
Atazanavir—Dyspnoea—Doxorubicin—testicular cancer	8.36e-05	0.000415	CcSEcCtD
Atazanavir—Feeling abnormal—Epirubicin—testicular cancer	8.35e-05	0.000414	CcSEcCtD
Atazanavir—Somnolence—Doxorubicin—testicular cancer	8.34e-05	0.000414	CcSEcCtD
Atazanavir—Gastrointestinal pain—Epirubicin—testicular cancer	8.29e-05	0.000411	CcSEcCtD
Atazanavir—Dyspepsia—Doxorubicin—testicular cancer	8.25e-05	0.000409	CcSEcCtD
Atazanavir—Decreased appetite—Doxorubicin—testicular cancer	8.15e-05	0.000404	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Doxorubicin—testicular cancer	8.09e-05	0.000402	CcSEcCtD
Atazanavir—Fatigue—Doxorubicin—testicular cancer	8.08e-05	0.000401	CcSEcCtD
Atazanavir—Urticaria—Epirubicin—testicular cancer	8.05e-05	0.000399	CcSEcCtD
Atazanavir—Pain—Doxorubicin—testicular cancer	8.02e-05	0.000398	CcSEcCtD
Atazanavir—Constipation—Doxorubicin—testicular cancer	8.02e-05	0.000398	CcSEcCtD
Atazanavir—Body temperature increased—Epirubicin—testicular cancer	8.01e-05	0.000397	CcSEcCtD
Atazanavir—Abdominal pain—Epirubicin—testicular cancer	8.01e-05	0.000397	CcSEcCtD
Atazanavir—Hypersensitivity—Methotrexate—testicular cancer	7.98e-05	0.000396	CcSEcCtD
Atazanavir—Asthenia—Methotrexate—testicular cancer	7.77e-05	0.000385	CcSEcCtD
Atazanavir—Feeling abnormal—Doxorubicin—testicular cancer	7.73e-05	0.000383	CcSEcCtD
Atazanavir—Gastrointestinal pain—Doxorubicin—testicular cancer	7.67e-05	0.00038	CcSEcCtD
Atazanavir—Pruritus—Methotrexate—testicular cancer	7.66e-05	0.00038	CcSEcCtD
Atazanavir—Hypersensitivity—Epirubicin—testicular cancer	7.47e-05	0.00037	CcSEcCtD
Atazanavir—Urticaria—Doxorubicin—testicular cancer	7.45e-05	0.00037	CcSEcCtD
Atazanavir—Abdominal pain—Doxorubicin—testicular cancer	7.41e-05	0.000368	CcSEcCtD
Atazanavir—Body temperature increased—Doxorubicin—testicular cancer	7.41e-05	0.000368	CcSEcCtD
Atazanavir—Diarrhoea—Methotrexate—testicular cancer	7.41e-05	0.000368	CcSEcCtD
Atazanavir—Asthenia—Epirubicin—testicular cancer	7.27e-05	0.000361	CcSEcCtD
Atazanavir—Pruritus—Epirubicin—testicular cancer	7.17e-05	0.000356	CcSEcCtD
Atazanavir—Dizziness—Methotrexate—testicular cancer	7.16e-05	0.000355	CcSEcCtD
Atazanavir—Diarrhoea—Epirubicin—testicular cancer	6.93e-05	0.000344	CcSEcCtD
Atazanavir—Hypersensitivity—Doxorubicin—testicular cancer	6.91e-05	0.000343	CcSEcCtD
Atazanavir—Vomiting—Methotrexate—testicular cancer	6.88e-05	0.000342	CcSEcCtD
Atazanavir—Rash—Methotrexate—testicular cancer	6.83e-05	0.000339	CcSEcCtD
Atazanavir—Dermatitis—Methotrexate—testicular cancer	6.82e-05	0.000338	CcSEcCtD
Atazanavir—Headache—Methotrexate—testicular cancer	6.78e-05	0.000337	CcSEcCtD
Atazanavir—Asthenia—Doxorubicin—testicular cancer	6.73e-05	0.000334	CcSEcCtD
Atazanavir—Dizziness—Epirubicin—testicular cancer	6.7e-05	0.000332	CcSEcCtD
Atazanavir—Pruritus—Doxorubicin—testicular cancer	6.63e-05	0.000329	CcSEcCtD
Atazanavir—Vomiting—Epirubicin—testicular cancer	6.44e-05	0.00032	CcSEcCtD
Atazanavir—Nausea—Methotrexate—testicular cancer	6.43e-05	0.000319	CcSEcCtD
Atazanavir—Diarrhoea—Doxorubicin—testicular cancer	6.42e-05	0.000318	CcSEcCtD
Atazanavir—Rash—Epirubicin—testicular cancer	6.39e-05	0.000317	CcSEcCtD
Atazanavir—Dermatitis—Epirubicin—testicular cancer	6.38e-05	0.000317	CcSEcCtD
Atazanavir—Headache—Epirubicin—testicular cancer	6.35e-05	0.000315	CcSEcCtD
Atazanavir—Dizziness—Doxorubicin—testicular cancer	6.2e-05	0.000308	CcSEcCtD
Atazanavir—Nausea—Epirubicin—testicular cancer	6.02e-05	0.000299	CcSEcCtD
Atazanavir—Vomiting—Doxorubicin—testicular cancer	5.96e-05	0.000296	CcSEcCtD
Atazanavir—Rash—Doxorubicin—testicular cancer	5.91e-05	0.000293	CcSEcCtD
Atazanavir—Dermatitis—Doxorubicin—testicular cancer	5.91e-05	0.000293	CcSEcCtD
Atazanavir—Headache—Doxorubicin—testicular cancer	5.87e-05	0.000291	CcSEcCtD
Atazanavir—Nausea—Doxorubicin—testicular cancer	5.57e-05	0.000276	CcSEcCtD
